AstraZeneca PLC (LON:AZN) has today updated on the Phase III DANUBE trial in bladder cancer. The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer..

AstraZeneca (LON:AZN) today announced that it has completed the previously communicated agreement with Atnahs Pharma to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose..

AstraZeneca (LON:AZN) has today announced that it has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally..

AstraZeneca plc (LON:AZN) has today announced its full year and Q4 2019 results. AstraZeneca delivered a year of strong revenue growth, supported by the launch of new medicines1 and further..

High-level results from the Phase III THALES trial showed AstraZeneca (LON:AZN) Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a statistically significant and clinically..

High-level results from the positive registrational Phase II trial DESTINY-Gastric01 showed AstraZeneca (LON:AZN) and Daiichi Sankyo Company, Limited’s Enhertu, achieved a statistically significant and clinically meaningful improvement in objective response rate..

AstraZeneca (LON:AZN) Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma,..

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (known as Merck & Co., Inc. inside the US and Canada) today announced that a supplemental New Drug Application for Lynparza has..

Following the recommendation from an independent Data Monitoring Committee, AstraZeneca (LON:AZN) has decided to close the Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) due to its low likelihood..

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) has today announced that a supplemental New Drug Application for..

AstraZeneca (LON:AZN) has announced today that Lokelma has been approved in China for the treatment of adult patients with hyperkalaemia. The approval by the National Medical Products Administration (NMPA) was..

AstraZeneca (LON:AZN) has today announced the US Food and Drug Administration has accepted a supplemental New Drug Application and granted Priority Review for Farxiga to reduce the risk of cardiovascular..

AstraZeneca (LON:AZN) and Daiichi Sankyo Company, have today announced that the US Food and Drug Administration has approved Enhertu for the treatment of adult patients with unresectable or metastatic HER2-positive..

AstraZeneca (LON:AZN) today announced that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This is the first approval by the National Medical..

AstraZeneca (LON:AZN) today announced that it has agreed to sell the commercial rights to Arimidex and Casodex in a number of European, African and other countries1 to Juvisé Pharmaceuticals. The..

AstraZeneca (LON:AZN) has completed an agreement to divest its commercial rights to Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. Financial considerations Under the terms of..

AstraZeneca (LON:AZN) has today announced that it has received marketing authorisation from China’s National Medical Products Administration for Imfinzi for the treatment of patients with unresectable, Stage III non-small cell..

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the companies have received marketing authorisation from..

AstraZeneca (LON:AZN) has agreed to sell the commercial rights to Seroquel and Seroquel XR in the US and Canada to Cheplapharm Arzneimittel GmbH. Seroquel and Seroquel XR, used primarily to..

AstraZeneca (LON:AZN) today announced that the US Food and Drug Administration has accepted a supplemental Biologics License Application and granted Priority Review for Imfinzi for the treatment of patients with..